Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using a proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The Company’s SMNH compounds are small segments of nucleic acids that are designed to selectively target and modulate the activity of specific proteins implicated in various disease states.
Spring Bank is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. It has designed SB 9200 to selectively activate within infected cells the cellular proteins retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. 

Company Growth (employees)
Type
Public
HQ
Hopkinton, US
Founded
2002
Size (employees)
15 (est)
Spring Bank Pharmaceuticals was founded in 2002 and is headquartered in Hopkinton, US

Spring Bank Pharmaceuticals Office Locations

Spring Bank Pharmaceuticals has offices in Hopkinton and Milford
Hopkinton, US (HQ)
86 South St
Milford, US
113 Cedar St

Spring Bank Pharmaceuticals Data and Metrics

Spring Bank Pharmaceuticals Financial Metrics

USD

Net income (Q1, 2017)

(6.5 m)

EBIT (Q1, 2017)

(4.5 m)

Market capitalization (22-Aug-2017)

123.3 m

Cash (31-Mar-2017)

14 m
Spring Bank Pharmaceuticals's current market capitalization is $123.3 m.
USDFY, 2016

R&D expense

14 m

General and administrative expense

5.7 m

Operating expense total

19.8 m

EBIT

(19.4 m)

Interest income

96 k

Net Income

(17.4 m)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

5.6 m2.9 m2.7 m2.5 m

General and administrative expense

1.2 m1.5 m1.5 m2 m

Operating expense total

6.8 m4.4 m4.2 m4.5 m

EBIT

(6.5 m)(4.3 m)(4.2 m)(4.5 m)

Interest expense

27 k

Interest income

17 k21 k27 k41 k

Net Income

(6.5 m)(10.8 m)(15 m)(6.5 m)
USDFY, 2016

Cash

10.7 m

Accounts Receivable

57.4 m

Inventories

840 k

Current Assets

25.6 m

PP&E

522 k

Accounts Payable

1.5 m

Current Liabilities

3.5 m

Total Liabilities

9.9 m

Additional Paid-in Capital

68.6 m

Retained Earnings

(51.5 m)

Total Equity

17 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

1.9 m11.3 m5.3 m14 m

Current Assets

7.2 m20.7 m16.7 m21.6 m

PP&E

498 k523 k496 k586 k

Accounts Payable

1.3 m2.9 m2.3 m1.9 m

Current Liabilities

2.8 m

Additional Paid-in Capital

48.3 m62.2 m62.7 m69 m

Retained Earnings

(40.7 m)(45 m)(49.1 m)(58 m)

Total Equity

7.6 m17.2 m13.5 m11 m
USDFY, 2016

Net Income

(17.4 m)

Depreciation and Amortization

118 k

Inventories

(527 k)

Accounts Payable

(812 k)

Cash From Operating Activities

(15.8 m)

Purchases of PP&E

(213 k)

Cash From Investing Activities

(6.5 m)

Cash From Financing Activities

28.7 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(6.5 m)(10.8 m)(15 m)(6.5 m)

Depreciation and Amortization

26 k57 k87 k36 k

Accounts Payable

(840 k)(564 k)148 k519 k

Cash From Operating Activities

(4.6 m)(8.9 m)(11.7 m)(4.1 m)

Purchases of PP&E

(97 k)(153 k)(156 k)(100 k)

Cash From Investing Activities

2.2 m103 k(1.9 m)7.6 m

Cash From Financing Activities

19.9 m15.8 m14.6 m

Spring Bank Pharmaceuticals Market Value History

Traffic Overview of Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals Online and Social Media Presence

Spring Bank Pharmaceuticals Company Life and Culture

You may also be interested in